blood DNA methylation

Overview

Blood DNA methylation refers to the pattern of methyl groups added to cytosine residues in DNA isolated from blood, most commonly at CpG sites. As an epigenetic mark, DNA methylation helps regulate gene activity without changing the underlying DNA sequence. In blood, these methylation patterns can reflect cell-type composition, metabolic state, inflammatory signaling, aging-related processes, and disease-associated regulatory changes, making them useful both for mechanistic studies and for biomarker development.

In biomedical research, blood DNA methylation is especially important because blood is accessible, allowing minimally invasive profiling across large cohorts. It has been used to study metabolic syndrome, obesity, diabetic complications, Cognitive decline, and aging, and to support multi-omics analyses in cancer and other diseases. Blood-based methylation signatures can also be integrated with gene expression, histone changes, phosphorylation, immune infiltration, and metabolic fingerprints to better understand disease biology.

Focus of Latest Publications

Recent studies have used blood DNA methylation as both a mechanistic readout and a biomarker source across metabolic, aging, and cancer-related contexts.

A 2026 study on promoter methylation of TXNIP and ADRB3 genes proposed these loci as potential blood-based biomarkers for metabolic syndrome. The authors emphasized that DNA methylation is involved in regulating genes linked to glucose and lipid metabolism, oxidative stress, and energy homeostasis. This places blood methylation in the context of Cardiometabolic comorbidity and broader metabolic dysfunction, where promoter methylation levels may help capture disease-associated regulatory shifts.

Blood DNA methylation was also used in a study of the pace of aging and mortality in the Norwegian cohort from the HUNT study. There, epigenetic clocks derived from blood DNA methylation data were used to estimate biological age and pace of aging, and these measures were associated with All-cause mortality. This work reinforces the role of blood methylation as a quantitative biomarker of systemic aging processes rather than a disease-specific marker alone.

In obesity research, a study of prepubertal children with obesity examined DNA methylation profiles to identify epigenetic markers predictive of success in a lifestyle intervention program. This indicates that blood methylation can be used to stratify individuals by likely response to intervention, supporting its potential utility in precision prevention and treatment planning.

Blood DNA methylation has also been linked to diabetic complications. A review on human DNA methylation biomarkers in diabetic complications noted that human studies have associated epigenetic modifications, particularly DNA methylation, with these outcomes, although clinical translation remains limited. This aligns with the broader theme that blood-based methylation markers may eventually help bridge association studies and clinical use, especially in metabolic disease.

Several recent publications used DNA methylation as part of broader multi-omics analyses in cancer. In prostate cancer progression, one study integrated DNA methylation, gene expression, and metabolic profiles from the same individuals to characterize normal, malignant, and aggressive prostate tissue. Although this was not limited to blood, it reflects the growing use of methylation data alongside Gene Expression Patterns, phosphorylation, and metabolic readouts to define disease states. Another pan-cancer analysis of LILRB4 integrated expression, genetic alterations, DNA methylation, phosphorylation, and immune infiltration, showing how methylation can be interpreted in relation to immune context and clinical outcomes across multiple tumor types.

In prostate cancer, a separate study reported a compensatory epigenetic switch between DNA methylation and H3K27me3-mediated repression as a barrier to epigenetic therapy in castration-resistant prostate cancer (CRPC). Although not a blood study, it highlights a key biological principle relevant to methylation research: DNA methylation can interact with histone changes to maintain gene repression, and these interactions may influence response to a hypomethylating agent or other epigenetic therapies.

Blood DNA methylation has also been discussed in relation to neurodegeneration. A study on methionine, homocysteine, and methylation levels suggested that metabolic factors, including DNA methylation, contribute to the pathogenesis of Cognitive decline in Alzheimer’s disease. This is consistent with prior observations that methylation-related pathways may connect one-carbon metabolism, oxidative stress, and brain aging.

Finally, a study on predictive epigenetic biomarkers of successful weight-loss intervention in children with obesity used DNA methylation profiling to identify markers associated with intervention response. This supports the idea that blood methylation can serve as a dynamic biomarker responsive to metabolic change, rather than a fixed disease label.

Key Publications

• Jun Promoter methylation of TXNIP and ADRB3 genes: potential blood-based biomarkers for metabolic syndrome. (Molecular biology reports, 2026, PMID 42319551): "Many studies have indicated that epigenetic mechanisms, particularly DNA methylation, play an important role in regulating genes involved in glucose and lipid metabolism, oxidative stress, and energy homeostasis."
• Jun Targeting the DNA methylation-H3K27me3 switch reverses castration resistance and immunosuppression via ADAMTS1-driven collagenolysis. (Proceedings of the National Academy of Sciences of the United States of America, 2026, PMID 42313934): "Here, we uncover a compensatory epigenetic switch between DNA methylation and H3K27me3-mediated repression as a critical barrier to epigenetic therapy in CRPC."
• Jun Urea cycle dysregulation and arginine pathways in the pathogenesis of NAFLD and NASH (Review). (International journal of molecular medicine, 2026, PMID 42272250): "Epigenetic modifications, notably DNA methylation and histone changes, contribute to this metabolic reprogramming."
• Jun Integrated multi-omics profiling uncovers the epigenetic, transcriptional, and metabolic landscape of prostate cancer progression. (BMC cancer, 2026, PMID 42260416): "to integrate DNA methylation, gene expression, and metabolic profiles derived from the same individuals, aiming to characterize the biological landscape of normal, malignant, and aggressive prostate tissue."
• Jun A pan-cancer landscape of LILRB4 identifies it as a context-dependent marker of the myeloid and antigen-presentation axis. (Translational oncology, 2026, PMID 42241991): "By integrating public multi-omics resources, we systematically profiled LILRB4 across expression, genetic alterations, DNA methylation, phosphorylation, and immune infiltration, and examined their associations with clinical outcomes."
• Jun Methionine, Homocysteine, and Methylation Levels Predict Cognitive Decline in Alzheimer's Disease. (CNS neuroscience & therapeutics, 2026, PMID 42201257): "...involves metabolic factors such as homocysteine, methionine, and DNA methylation in its pathogenesis."
• Jun DNA methylation is associated with phenotypic divergence between the dermatophytes Trichophyton rubrum and Trichophyton violaceum. (Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026, PMID 42223793): "suggesting the involvement of epigenetic regulation beyond genetic determinants."
• May Predictive epigenetic biomarkers of successful weight-loss intervention in pre-pubertal children with obesity. (Clinical epigenetics, 2026, PMID 42210364): "This study investigated DNA methylation profiles in prepubertal children living with obesity to identify possible epigenetic markers that could predict the success of weight loss interventions."
• May Pan-cancer neurotransmitter receptor alterations define neuroregulatory subtypes with prognostic significance. (Cell reports, 2026, PMID 42096332): "NTR expression was widely dysregulated and associated with altered DNA methylation, microRNA (miRNA) expression, and patient prognosis."
• May Human DNA methylation biomarkers in diabetic complications: from association to clinical translation. (Epigenomics, 2026, PMID 42192279): "Over the past decade, human studies have linked epigenetic modifications, particularly DNA methylation, to diabetic complications, yet translation into clinically useful biomarkers has been slow."